KMV Advisory is a Life Science Tools, Diagnostics and TechBio strategy practice for founders, investors, and established companies. It brings the judgment of someone who has run the P&L, closed the deals, and led from the CEO's chair to your highest-stakes commercial decisions.
Most strategy advisors have studied this industry. KMV Advisory is built by someone who has run it.
The practice is grounded in a career that has carried global P&Ls from $100M to more than $2B, guided a company to a successful exit from the CEO's chair, and championed more than half a dozen acquisitions across Genomics, Diagnostics, and Life Science Tools. Much of that career was spent building and scaling the instrument, reagents and consumables, informatics, and service businesses at the heart of Life Science Tools, the recurring-revenue model that turns a single product into a business that compounds. When an engagement calls for more, the practice draws on a small circle of trusted specialists who have operated at the same level, so the depth on hand always fits the problem. That operating experience sits behind every engagement, with respect for how hard this work is and for the fact that the people who carry the plan forward will be your own. That experience spans North America, Europe, and Asia, where the same technology often meets very different commercial, regulatory, and reimbursement realities.
Define your market, prove your wedge, build a commercial and fundraising story investors actually believe, and have a steady sounding board as you grow into the CEO seat.
Commercial and technical diligence, target identification, and portfolio support, grounded in decades inside the companies that built these markets.
A seasoned operator to pressure-test the deal: the commercial thesis, the technology, the team, and the real path to value, read by someone who has run businesses like the one you are buying.
Growth strategy, entry into new geographies and segments, M&A and integration, and a clear-eyed AI and TechBio playbook for deciding whether to build, buy, or partner.
The work here comes from someone who has actually run these businesses, including the instrument, reagents and consumables, informatics, and service P&Ls that define Life Science Tools and Diagnostics. That means advice shaped by having owned the number and lived with the results, across the full arc of one of these companies: a pre-seed platform and a multinational division, the founder's chair and the acquirer's, the operator's seat and the investor's. When a question runs wider than one person should take on alone, the practice brings in proven, like-minded advisors, so the work scales to what the moment requires while the standard of judgment holds.
Genomics, Spatial Biology, Diagnostics including Point of Care, and AI-driven Discovery are where that experience already runs deep, so little time is lost getting up to speed on your space. Decades of relationships across industry, the clinic, and the capital markets mean an honest read and, when it helps, a warm introduction to the right person. And because markets in the United States, Europe, and Asia each reward different strategies, the plan you get is shaped by years of working across all of them, calibrated to how your market really buys, regulates, and reimburses.
Every recommendation here runs through one filter: will it move the number, with the team, the capital, and the timeline you actually have? That is the question an operator wakes up with, and it changes the advice. It keeps strategy honest about what execution really costs, candid about the trade-offs, and focused on the handful of moves that decide the outcome. A plan that holds up once it meets the market is the rarer thing, and the one worth having. That is the lens we bring to every engagement.
Kamni and her network of advisory partners took a strong scientific story and turned it into a fundable strategy. They reset our strategic plan, sharpened our pitch, and made the introductions to the B2B partners who mattered most for licensing. Having that combination of strategy and relationships in one place changed our trajectory.